Dechert advised Servier in connection with its collaboration agreement in cardiovascular disease with Amgen. Under the terms of the agreement, Amgen has obtained commercial rights in the U.S. to Servier's novel oral drug, ivabradine, for chronic heart failure and stable angina. Amgen has also received an option to develop and commercialize Servier's investigational molecule, S38844, for cardiovascular diseases in the U.S.

Additionally, Servier has obtained rights to develop and commercialize omecamtiv mecarbil in the European Union. Omecamtiv mecarbil is an activator of cardiac myosin under license by Cytokinetics, which is currently being tested for potential applications in the treatment of heart failure in patients with systolic dysfunction.

A cross-border team from Dechert led by partner Emmanuelle Trombe advised Servier in this transaction. The team included partners Jonathan Schur and James Fishkin and associates Anthony Paronneau, Guillaume Briant, Shirley Wang and Cara Schmidt.